Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. Show more

Location: 275 Shoreline Drive, Redwood City, CA, 94065, United States | Website: https://www.rezolutebio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

303.2M

52 Wk Range

$1.07 - $11.46

Previous Close

$3.27

Open

$3.28

Volume

1,822,542

Day Range

$3.11 - $3.51

Enterprise Value

152.5M

Cash

152.2M

Avg Qtr Burn

-17.62M

Insider Ownership

10.52%

Institutional Own.

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ersodetug Details Tumor Hyperinsulinism (Tumor HI)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ersodetug Details Congenital Hyperinsulinism	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.